SCHEMBL1029022

SCHEMBL1029022

O=C(O)C1COOC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27745365 0.97
SCHEMBL28352421 0.97
SCHEMBL1816755 0.81
SCHEMBL695096 0.80
SCHEMBL28176525 0.77 TSHR (0.39)
SCHEMBL1813417 0.75
Cyclopropane Carboxylic Acid SCHEMBL28307616 0.73 LMNA (0.46)
SCHEMBL2489106 0.72 CYP2C19 (0.33)
SCHEMBL2492164 0.72 CYP2C19 (0.33)
SCHEMBL1818943 0.71 APLNR (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104334170-B Use of NEU1 sialidase inhibitors in cancer therapy 迈伦·R·谢夫丘克 2020-02-07 CN claimed
CN-1149296-A Rapamycin hydroxyesters, process for their preparation and pharmaceutical compositions containing them AMERICAN HOME PROD (US) 1997-05-07 CN claimed
EP-0426253-A1 Process for the separation of R and S-2,2R1, R2-1,3-dioxolane-4-carboxylic acid SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1991-05-08 EP claimed
US-20250075147-A1 FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS OSMO LABS, PBC 2025-03-06 US disclosed
CN-115557933-A Bruton tyrosine kinase and mutant degradation agent, composition and application thereof 杭州和正医药有限公司 2023-01-03 CN disclosed
CN-113891879-A 3, 6-disubstituted-2-pyridine aldoxime skeletons 国家科学研究中心 2022-01-04 CN disclosed
US-20210289794-A1 COMPOSITIONS AND RELATED METHODS FOR AGRICULTURE FLAGSHIP PIONEERING INNOVATIONS V, INC. 2021-09-23 US disclosed
US-10800806-B2 Sterol derivatives and use thereof for treating diseases involving transformed astrocyte cells or for treating malignant haemopathies BETA INNOV (FR) 2020-10-13 US disclosed
CN-104334170-B Use of NEU1 sialidase inhibitors in cancer therapy 迈伦·R·谢夫丘克 2020-02-07 CN disclosed
CN-109641866-A The manufacturing method of monoglyceride 花王株式会社 2019-04-16 CN disclosed
CN-109641865-A Process for producing glycerate 花王株式会社 2019-04-16 CN disclosed
WO-2004028445-A2 PROCESSES FOR PREPARING 1,3-DIOXOLANE NUCLEOSIDES PHARMASSET INC. (US) 2004-04-08 WO disclosed
CN-1414951-A Drug discharge pump inhibitor FUNDAMENTAL THERAPEUTICAL INC (US) 2003-04-30 CN disclosed
CN-1400975-A Purine derivatives PFIZER LTD (US) 2003-03-05 CN disclosed
CN-1378551-A Purine derivatives PFIZER LTD (US) 2002-11-06 CN disclosed
CN-1059905-C Rapamycin hydroxyesters, process for their preparation and pharmaceutical compositions containing them AMERICAN HOME PROD (US) 2000-12-27 CN disclosed
CN-1149296-A Rapamycin hydroxyesters, process for their preparation and pharmaceutical compositions containing them AMERICAN HOME PROD (US) 1997-05-07 CN disclosed
EP-0426253-A1 Process for the separation of R and S-2,2R1, R2-1,3-dioxolane-4-carboxylic acid SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1991-05-08 EP disclosed
EP-0426253-A1 Process for the separation of R and S-2,2R1, R2-1,3-dioxolane-4-carboxylic acid SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1991-05-08 EP disclosed
EP-0405691-A1 A process for the preparation of a S-2,2-R1,R2-1,3-dioxolane-4-methanol SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1991-01-02 EP disclosed